We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Dr Shaji Kumar, one of our Editors-in-Chief for touchREVIEWS in Oncology & Haematology, discusses his presentation at the 63rd ASH Annual Meeting & Exposition on the final overall survival results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Intro: 00:12-00:18 Questions 1. Could […]
Professor Michael Mauro (Memorial Sloan Kettering Cancer Center, New York City, NY, USA) discusses the 48-week update from the ASCEMBL trial, a multicenter, open-label, phase III study of the efficacy and safety of asciminib, a first-in-class STAMP inhibitor, vs Bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: […]
touchONCOLOGY editorial board member Professor Robin Foà (Sapienza University of Rome, Italy) discusses his recent phase II study exploring the benefits, efficacy and safety of tyrosine kinase inhibitors dasatinib–blinatumomab for the treatment of Ph-positive acute lymphoblastic leukemia in adults. Questions What is the rationale for the use of dasatinib plus glucocorticoids, followed by blinatumomab, rather […]
We were delighted to catch up with Dr Pinkal Desai (Weill Cornell Medical College, New York City, NY, USA) to discuss the report from the American Society of Hematology Research Collaborative (ASH RC) Data Hub on clinical predictors of outcome in adult patients with acute leukemias and myelodysplastic syndrome and COVID-19 infection. Questions 1. Prior […]
Dr Aditya Bardia (Harvard Medical School, Boston, MA, USA) discusses the results of the phase III EMERALD trial, exploring elacestrant, an oral selective estrogen receptor degrader, vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer following progression on prior endocrine and CDK4/6 inhibitor therapy. These results were presented at the San Antonio Breast […]
Dr Nancy Lin (Dana-Farber Cancer Institute, Boston, MA, USA) discusses the updated results of the phase II HER2CLIMB study, which assessed tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases. These results were presented at the San Antonio Breast Cancer Symposium 2021. Questions 1. […]
Dr Marta Vaz Batista (Hospital Fernando Fonseca, Amadora, Portugal) discusses the preliminary results from the DEBBRAH phase II study, exploring trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement. These results were presented at the San Antonio Breast Cancer Symposium 2021. Questions 1. Could you tell us a […]
Professor David Potter (Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA) discusses the results of the I-SPY 2 trial, the evaluation of tucatinib + (paclitaxel + pertuzumab + trastuzumab) in high-risk HER2 positive stage II/III breast cancer. These results were presented at the San Antonio Breast Cancer Symposium 2021. Question: Please can you summarise […]
Get the latest clinical insights from touchONCOLOGY